Unlocking the Potential of KPNA1: A Potent Drug Target and Biomarker

Target Name: KPNA1

NCBI ID: G3836

KPNA1

Unlocking the Potential of KPNA1: A Potent Drug Target and Biomarker

Introduction

KPNA1, a gene located on chromosome 12, has been identified as a potential drug target and biomarker. The KPNA1 gene encodes a non-coding RNA molecule that plays a critical role in the regulation of gene expression and has been associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

KPNA1: A Direct Hit on Cancer-related gene expression

KPNA1 has been shown to be involved in the regulation of cancer cell growth and progression. Studies have found that KPNA1 plays a key role in a variety of cancers, such as lung cancer, liver cancer, breast cancer, etc. The level of KPNA1 gene expression is closely related to the survival rate, disease severity and treatment response of cancer patients.

KPNA1: a potential drug target

KPNA1 is considered a potential drug target due to its critical role in a variety of cancers. Currently, there are many drug research projects targeting KPNA1 being carried out, aiming to inhibit the growth and spread of cancer cells by interfering with the activity of KPNA1. These drug studies include gene silencing technology, KPNA1 inhibitors, KPNA1-targeted anti-tumor drugs, etc.

KPNA1: a potential biomarker

In addition to being a drug target, KPNA1 is also considered a potential biomarker. Many cancer patients lack symptoms in the early stages of the disease, making early diagnosis difficult. However, some tumor gene expression levels change, leading to worsening of symptoms in cancer patients. KPNA1 is a gene that can serve as a potential biomarker for tumor gene expression.

Using differential expression analysis technology of KPNA1, tumor patients with increased or decreased KPNA1 expression levels can be detected. By comparing KPNA1 expression levels in tumor tissue and non-tumor tissue, tumor recurrence and treatment response can be determined. In addition, because KPNA1 is expressed in a variety of cancers, it can be used as an important biological indicator for the prognosis of tumor patients.

Summarize

KPNA1 is a potential drug target and a potential biomarker. By inhibiting the activity of KPNA1, the growth and spread of cancer cells can be inhibited, providing better therapeutic effects for tumor patients. Currently, many drug research projects targeting KPNA1 are being carried out and are expected to bring better treatment prospects to tumor patients.

Protein Name: Karyopherin Subunit Alpha 1

Functions: Functions in nuclear protein import as an adapter protein for nuclear receptor KPNB1. Binds specifically and directly to substrates containing either a simple or bipartite NLS motif. Docking of the importin/substrate complex to the nuclear pore complex (NPC) is mediated by KPNB1 through binding to nucleoporin FxFG repeats and the complex is subsequently translocated through the pore by an energy requiring, Ran-dependent mechanism. At the nucleoplasmic side of the NPC, Ran binds to importin-beta and the three components separate and importin-alpha and -beta are re-exported from the nucleus to the cytoplasm where GTP hydrolysis releases Ran from importin. The directionality of nuclear import is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus. In vitro, mediates the nuclear import of human cytomegalovirus UL84 by recognizing a non-classical NLS

The "KPNA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KPNA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets